-+ 0.00%
-+ 0.00%
-+ 0.00%

Scotts Miracle Gro (SMG) After Mixed Earnings And Dividend Decision Has Valuation In Focus

Simply Wall St·07/29/2026 20:11:22
语音播报

Mixed earnings and dividend decision put Scotts Miracle-Gro in focus

Scotts Miracle-Gro (SMG) is back on investors' radar after reporting third quarter earnings that combined higher sales with lower net income, alongside a Board approved cash dividend of $0.66 per share.

See our latest analysis for Scotts Miracle-Gro.

Scotts Miracle-Gro’s recent earnings release, which showed higher sales but lower net income, appears to be driving fresh interest. The latest 1-day share price return of 4.64% has contributed to a 23% year-to-date share price return and a 12.58% total shareholder return over the past year. This suggests momentum has been building recently despite a 50.05% total shareholder return decline over five years.

If this mix of earnings and dividends has you reassessing your watchlist, it could be a good moment to widen the lens and check out 18 top founder-led companies

After the latest jump in Scotts Miracle-Gro, the share price now sits close to some analyst targets yet still below one estimate of fair value. How wide is that gap in reality, and what does it imply for valuation next?

Most Popular Narrative: 68.1% Overvalued

At a last close of $73.10, the most followed narrative on Scotts Miracle-Gro puts fair value closer to $43.49, which is a sizeable gap for investors to consider.

This is not a hypergrowth story. It is a durability story. As food security, indoor agriculture, and yield efficiency gain importance globally, companies with cultivation expertise stand to benefit quietly rather than explosively.

Read the complete narrative.

Want to understand why this narrative still assigns meaningful value to Scotts Miracle-Gro despite a tough few years? The fair value hinges on how stable margins, measured revenue expansion and a future earnings profile fit together over time. The full narrative spells out the cash flow path that supports that $43.49 figure.

Result: Fair Value of $43.49 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Scotts Miracle-Gro still faces risks if cannabis cultivation remains pressured or if controlled-environment projects slow. This could challenge that durability-focused narrative.

Find out about the key risks to this Scotts Miracle-Gro narrative.

Another View on Scotts Miracle-Gro’s Valuation

The user narrative describes Scotts Miracle-Gro as 68.1% overvalued at $73.10 compared with a fair value of $43.49. Our DCF model comes out differently. It points to a future cash flow value of $82.03, which implies the stock trades at about an 11% discount instead.

This gap between a narrative fair value and a cash flow based estimate raises a simple question for investors: Which set of assumptions about margins, growth and risk feels closer to how Scotts Miracle-Gro will actually run its business over time, and which one do you want to lean on when building your thesis?

Look into how the SWS DCF model arrives at its fair value.

SMG Discounted Cash Flow as at Jul 2026
SMG Discounted Cash Flow as at Jul 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Scotts Miracle-Gro for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment on Scotts Miracle-Gro split between risks and rewards, this is a moment to move quickly and test the numbers yourself. To weigh both sides of the story in one place, start with 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Scotts Miracle-Gro?

If Scotts Miracle-Gro has sharpened your focus, use this momentum to scan other opportunities before they move without you. The Screener helps you act with intention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.